세계의 소프트 미스트 흡입기 시장 보고서(2025년)
Soft Mist Inhalers Global Market Report 2025
상품코드 : 1760717
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

소프트 미스트 흡입기 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 8.3%의 연평균 복합 성장률(CAGR)로 42억 4,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 전 세계 오염 수준 증가, 노인 인구 증가, 천식 및 COPD 발병률 증가, 비침습적 약물 전달 방법의 채택 증가, 신흥 시장에서의 의료 인프라 확대 등에 기인합니다. 예측 기간 동안 주요 동향으로는 휴대가 간편하고 사용하기 쉬운 흡입기에 대한 수요 증가, 친환경적이고 지속 가능한 흡입기 설계에 대한 관심 증가, 흡입기와 디지털 헬스 솔루션의 통합 증가, 개인화된 환자 중심 치료로의 전환, 약물 전달 기술의 발전 등이 있습니다.

천식 유병률 증가는 향후 몇 년 동안 소프트 미스트 흡입기 시장의 성장을 가속할 것으로 예측됩니다. 천식은 기도의 염증과 협착을 일으켜 호흡 곤란을 유발하는 만성 호흡기 질환입니다. 천식 환자 증가는 주로 대기 오염에 대한 노출 증가로 인해 호흡기 상태를 악화시키고 시간이 지남에 따라 폐 기능에 손상을 입힐 수 있습니다. 소프트 미스트 흡입기는 천식 및 기타 만성 폐쇄성 폐질환 관리에 있어 미세하고 천천히 움직이는 미스트 형태의 약물을 폐에 직접 분사하여 약물의 침착을 개선하고 최소한의 노력으로 호흡기를 완화합니다. 예를 들어, 2023년 12월 호주 통계청은 2022년 호주에서 약 280만 명(인구의 10.8%)이 천식을 앓고 있다고 보고했습니다. 또한 천식 환자 3명 중 1명(33.9%)이 매일 천식약을 사용하고 있다고 보고했습니다. 결과적으로 천식과 만성폐쇄성폐질환(COPD)의 유병률 증가는 소프트미스트 흡입기 시장의 성장에 기여하고 있습니다.

소프트 미스트 흡입기(SMI) 시장의 주요 기업들은 시장에서의 입지를 강화하고 제품 접근성을 높이기 위해 전략적 파트너십에 집중하고 있습니다. 이들 기업은 연구 기관, 기술 기업, 지역 의료 서비스 제공업체와 협력하여 각자의 강점을 결합하여 혁신적이고 환자 중심의 흡입 요법을 제공하는 데 있어 경쟁 우위를 확보하고자 합니다. 예를 들어, 2024년 제네릭 및 맞춤형 흡입기 장치 설계 및 공급을 전문으로 하는 영국 기업 Merxin Ltd.는 독일 의료기기 제조업체인 OECHSLERhealth와 파트너십을 체결했습니다. 이 파트너십은 소프트 미스트 흡입기(SMI) 파워하우스(Powerhouse)의 출범으로 이어졌습니다. 이 구상은 의약품 개발자 시장 진입을 가속화하기 위한 것으로, OECHSLER Health와의 제휴를 통해 OECHSLER Health의 제조 및 조립 전문 지식과 메르신의 독자적인 SMI 설계를 결합하는 것을 포함합니다. 양사는 지적재산권 보호, 성능, 신뢰성, 신뢰성, 속도, 비용 효율성 측면에서 새로운 업계 표준을 세울 계획입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

LSH
영문 목차

영문목차

A soft mist inhaler (SMI) is an inhalation device that delivers medication as a slow-moving, long-lasting aerosol mist, generated without the use of propellants. This method allows for better lung deposition and easier inhalation, making it especially beneficial for patients with limited inspiratory capacity.

The main product types of soft mist inhalers include portable soft mist inhalers and stationary soft mist inhalers. Portable soft mist inhalers are designed for delivering medication in the form of a fine mist for treating respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD). The various applications of soft mist inhalers include asthma, COPD, and other respiratory diseases. They are used by several end-users, including hospitals and clinics, home care settings, and others.

The soft mist inhalers market research report is one of a series of new reports from The Business Research Company that provides soft mist inhalers market statistics, including the soft mist inhalers industry global market size, regional shares, competitors with the soft mist inhalers market share, detailed soft mist inhalers market segments, market trends, and opportunities, and any further data you may need to thrive in the soft mist inhalers industry. This soft mist inhalers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The soft mist inhalers market size has grown strongly in recent years. It will grow from $2.84 billion in 2024 to $3.09 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the increasing prevalence of respiratory diseases, the growing adoption of inhaler devices for asthma and COPD treatment, rising healthcare awareness, growing demand for advanced healthcare solutions, and increasing healthcare expenditure and access.

The soft mist inhalers market size is expected to see strong growth in the next few years. It will grow to $4.24 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth during the forecast period can be attributed to rising global pollution levels, a growing geriatric population, an increasing incidence of asthma and COPD, the rising adoption of non-invasive drug delivery methods, and expanding healthcare infrastructure in emerging markets. Key trends in the forecast period include growing demand for portable and easy-to-use inhalers, a focus on eco-friendly and sustainable inhaler designs, increasing integration of digital health solutions with inhalers, a shift toward personalized and patient-centric treatments, and advancements in drug delivery technology.

The growing prevalence of asthma is expected to drive the expansion of the soft mist inhalers market in the coming years. Asthma is a chronic respiratory disease that leads to inflammation and narrowing of the airways, making breathing difficult. The rise in asthma cases is mainly attributed to the increasing exposure to air pollution, which worsens respiratory conditions and damages lung function over time. Soft mist inhalers assist in managing asthma and other chronic obstructive pulmonary diseases by delivering a fine, slow-moving mist of medication directly to the lungs, improving drug deposition and providing respiratory relief with minimal effort in coordination. For example, in December 2023, the Australian Bureau of Statistics reported that in 2022, about 2.8 million people in Australia (10.8% of the population) had asthma. Additionally, one in three individuals with asthma (33.9%) reported using asthma medication daily. Consequently, the rising prevalence of asthma and chronic obstructive pulmonary disease (COPD) is contributing to the growth of the soft mist inhalers market.

Key players in the soft mist inhalers (SMIs) market are focusing on strategic partnerships to increase their market presence and improve product accessibility. These companies aim to combine their strengths to gain a competitive advantage in delivering innovative, patient-focused inhalation therapies by collaborating with research organizations, technology firms, and local healthcare providers. For instance, in 2024, Merxin Ltd., a UK-based company specializing in the design and supply of generic and customized inhaler devices, formed a partnership with OECHSLERhealth, a German manufacturer of medical devices. This collaboration led to the launch of the Soft Mist Inhalers (SMI) Powerhouse. This initiative aims to speed up market entry for drug developers and includes a partnership with OECHSLER Health to combine its manufacturing and assembly expertise with Merxin's proprietary SMI design. Together, they plan to set new industry standards in intellectual property protection, performance, reliability, speed, and cost-effectiveness.

In January 2024, Recipharm AB, a Sweden-based pharmaceutical company, joined forces with Medspray to expand the use of soft mist inhaler (SMI) technology beyond conventional respiratory treatments by developing soft mist nasal delivery devices for both single and combination drug products. This partnership aligns with Recipharm's strategy to innovate drug delivery solutions and diversify its offerings in advanced inhalation technologies. Medspray, based in the Netherlands, specializes in soft mist inhalers and spray delivery systems.

Major players in the soft mist inhalers market are Merck & Co., Novartis International AG, AstraZeneca plc, GlaxoSmithKline plc, Boehringer Ingelheim Pharma GmbH & Co. KG, Philips Respironics Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., 3M Healthcare, Omron Healthcare Inc., AptarGroup Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals plc, Mundipharma International Limited, Hovione Ltd., Vectura Group Limited, MannKind Corporation, H&T Presspart Ltd., Sunovion Pharmaceuticals Inc., Merxin Ltd., Adherium Limited.

North America was the largest region in the soft mist inhalers market in 2024. The regions covered in soft mist inhalers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the soft mist inhalers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The soft mist inhalers market consists of sales of respimat inhalers, tiotropium, and ipratropium. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Soft Mist Inhalers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on soft mist inhalers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for soft mist inhalers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The soft mist inhalers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Soft Mist Inhalers Market Characteristics

3. Soft Mist Inhalers Market Trends And Strategies

4. Soft Mist Inhalers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Soft Mist Inhalers Growth Analysis And Strategic Analysis Framework

6. Soft Mist Inhalers Market Segmentation

7. Soft Mist Inhalers Market Regional And Country Analysis

8. Asia-Pacific Soft Mist Inhalers Market

9. China Soft Mist Inhalers Market

10. India Soft Mist Inhalers Market

11. Japan Soft Mist Inhalers Market

12. Australia Soft Mist Inhalers Market

13. Indonesia Soft Mist Inhalers Market

14. South Korea Soft Mist Inhalers Market

15. Western Europe Soft Mist Inhalers Market

16. UK Soft Mist Inhalers Market

17. Germany Soft Mist Inhalers Market

18. France Soft Mist Inhalers Market

19. Italy Soft Mist Inhalers Market

20. Spain Soft Mist Inhalers Market

21. Eastern Europe Soft Mist Inhalers Market

22. Russia Soft Mist Inhalers Market

23. North America Soft Mist Inhalers Market

24. USA Soft Mist Inhalers Market

25. Canada Soft Mist Inhalers Market

26. South America Soft Mist Inhalers Market

27. Brazil Soft Mist Inhalers Market

28. Middle East Soft Mist Inhalers Market

29. Africa Soft Mist Inhalers Market

30. Soft Mist Inhalers Market Competitive Landscape And Company Profiles

31. Soft Mist Inhalers Market Other Major And Innovative Companies

32. Global Soft Mist Inhalers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Soft Mist Inhalers Market

34. Recent Developments In The Soft Mist Inhalers Market

35. Soft Mist Inhalers Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기